Screening for neoplastic liver lesions: How early can we get?

Pesquisaje de lesiones neoplásicas de hígado: ¿Cómo llegar a ellas antes?

• Nancy Escalante Bencomo Hospital Clínico de Maracaibo https://orcid.org/0000-0003-4308-6564

DOI: https://doi.org/10.5281/zenodo.5120837

Keywords: hepatocellular carcinoma, surveillance, screening, risk population, detection

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers, worldwide representing the fifth most common cancer and the second cause of cancer related mortality. Cirrhosis has been recognized as the most important risk factor for the development of HCC; however it can also occur in patients without cirrhosis. HCC is often asyntomatic until an advanced stage when the therapeutic and effective options are limited. Therefore a diagnosis is necessary in the early stages when the tumor is susceptible to being treated thereby improving survival. For these reasons its mandatory the identification of the population at risk in order to apply screening and surveillance programs, to reduce the mortality. These must be cost effective, being the ultrasound alone or in combination with the alpha fetoprotein every 6 months, recommended by the liver societies.

References

World Health Organisation International Agency for Research on Cancer Globalcan 2012,Summary Statistic http://gco.iarc.fr/today/home

Forner A,Reig M, Bruix J, Hepatocellular carcinoma. Lancet 2018;391:1301-1314

Fateen W, Ryder SD Screening for hepatocellular carcinoma: patient selection and perspectives J Hepatocell Carcinoma 2017 May17;4:71-79. Doi:10.2147/JHC.S105777.PMID:2888553624;PMCID:PMC5440035.

De Lope CR,Tremosini S,Forner A Reig M, Bruix J. Management of HCC J. Hepatol 2012;56:Suppl 1: S75-S87 [PMID:2300468 DOI:10.1016/S0168-8278(12))60009

Harris RP, Wilt TJ, Qaseem A, A value framework for cancer screening:advice for high-value care from the American College of Physicians Ann Intern Med 2015;162:12-717

Giannini EG, Cuchetti A, Erroi V, Garoti F, Odaldi F,Trevisan F World J Gastroenterol 2013, 21;19(47):8808-88821

European association for the Study of the Liver EASL Clinical Practice Guidelines :management of hepatocellular carcinoma J.Hepatol 2018, Jul;69(1):182-236

Heinbach JK, Kulik LM, Finn RS , et al : AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology.2018;67:358-380

Omata M, Cheng AL, Kokudo N et al. Asian-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: an update.Hepatol int 2017;11:317-370.

Sarasin FP, Giostra E, Hadengue A. Cost-efectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrosis. Am J Med.1996 Oct;101(4):422-34.doi:10,1016/S0002-9343(96)00197-0.PMID:8873514.

Sherman M, Furlan A Marin D Agnello F,Martino Di M, Marco Di V, et al Surveillance for hepatocellular carcinoma. Best Prac. Res. Clin Gastroenterol.2014;28:83-973

Diaz-Gonzalez A, Forner A . Surveillance for hepatocellular carcinoma. Best Prac Res Clin Gastroenterol 2016;30:1001-1010.

Trevisani F, Santi V, Gramenzi A, Di Nolfo MA , l Poggio P, D Benvegnu L et al. Surveillance for early diagnosis of hepatocellular carcinoma :is it effective in intermediate/advanced cirrhosis Am J Gastroenterol, 102(11), 2448-2457. http://doi.org/10.11/j.1572-0241.2007.01395.

Marrero JA, Kulik LM, Sirlin CB et al Diagnosis, staging and management of hepatocellular carcinoma:2018 Practice Guidance by the American Association for the Study of Liver Diseases . Hepatology ,2018;68:723-750.

Loomba R, Liu J, Yang HI, Lee MH, Lu SN ,Wang LY et al .Synergistic effects of family history of hepatocellular carcinoma and hepatitis B visrus infection on risk for incident hepatocellular carcinoma .Clin Gastroenterol Hepatol 2013;11:1636-1645.e3

Terrault NA, Bzowej NH, Chang KM, et el. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283

Frenette CT, Isaacson AJJ, Bargellini I, et al. A practical guideline for hepatocellular carcinoma screening in patients at risk. Mayo Clin Proc Innov Qual Outcomes.2019;3:302-310.

Lok AS, Seef LB, Morgan TR , Di Bisceglie AM, Sterling RK, Curto TM et al Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease Gastroenterology 2009;136:138-148.

Masuzaki R, Tateishi R, Yoshida H, Sato S, Kato N, Kanai F, et al. Risk assesment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography J Clin gastroenterol 2008;42:839-843.

Yoshida H, Shiratori Y, Moriyama M., Arakawa Y, Ide T, Sata M et al, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance programs of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan Amm Intern Med 1999;131-174

Ioannu GN, Green PK, Berry K . HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma Hepatol 2017;Sepp 5.piiiS0168-8278(17)3273-0.doi:190,1016/j.jhep.2017.08.030

Perumpail RB, Wong RJ AhmedA. Et al. Hepatocellular carcinoma in the setting of the nonalcoholic fatty liver disease and the metabolic syndrome:US experience. Dig Dis sci 60, 3142-3148 (2015). http:/doi.org10.1007/s10620-015-3821-7.

Deugnier YM, Guyader D, Crantockk L, Lopez JM, Turlin B Yaouang J et al. Primary liver cancer in genetic hemocromatosis: a clinical, pathological ,, and pathogenetic study of 54 cases. Gastroenterology. 1993 Jan:104(1):228-34.doi:10.1016/0016

Perlmutter DH .Pathogenesis of crhonic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006 Aug;60(2):233-8.doi:10.1203/01.pdr.00002288350.61496.90.PMID:16864711.

Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis:surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis . Aliment Pharmacol Ther. 2009 Jul;30((1):3-47.doi:10.1111/j.1365-2036.2009.04014.x.Epub 2009 Apr 8.PMID

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma:a cost effectiveness analysis. Gut.2001 Feb;48 (2):251-9.doi:10.1136/gut.48.2.251

Gupta S, Bent S Kohwels J, Test characteristics of alpha fetoprotein for detecting hepatocellullar carcinoma in patients with hepatitis C A systemic review and critical analysis. Ann Intern Med 2003 Jul 1;139(1):46-50.doi 10.7326/0003-48819-139-1-200307010-00012.PMID:128834318.

Di Bisceglie AM, Sterling RK, Chung RT et al Serum alpha fetoprotein levels in patients with advanced hepatitis C:results from the HALT-C trial J Hepatol.2005 Sep;43(3):434-41.doi:10.1016/j.jhep.2005.03.019.PMID 16136646

Giannini EG Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P et al Alpha fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012 Oct;56(4): 1371-9.doi:10.1002/hep.25814. PMID:22535689

Sherman M serological surveillance for hepatocellular carcinoma: time to quit J Hepatol 2010;52:614-615 PMID:20185193 doi:10.1016/j.hep.2009.11.026

Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan:Consensus-based Clinical Practice Guidelines proposed by the Japan Society of Hepatology ((JSH) 2010: updated version Dig Dis 2011;29:339-364 PMID:21829027.doi:10.1159/000327577

Johnson PJ, Pirrie SJ, Cox TF, Berhanes, Teng MJ, Palmer DT et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):144-53.doi:10.1158/1055-9965.EPI-13-0870.Epub 2013 Nov 12.PMID:24220911

Sato T, Tateishi R, Yoshida H , Ohki T, Masuzaki R, Imamura J, et al Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C Hepatol Int. 2009 Dec;3(4):544-50.doi:10.1007/s12072-009-9145-y. Epub 2009 Aug 6 PMID: 19669240;PMCID:PPMC2790585